A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects

Overview

Journal Immunotargets Ther

Publisher Dove Medical Press

Specialty Allergy & Immunology

Date 2022 Oct 6

PMID 36199734

Authors

Muhammet Celik

Brian Fuehrlein

Affiliations

Soon will be listed here.

Abstract

Substance use disorders (SUDs) have been a major public health challenge for decades and continue to cause significant morbidity and mortality worldwide. Due to limitations in pharmacologic treatment options, there remains a significant need for the development of novel immunotherapeutic approaches. In this review, we discuss the therapeutic potential of vaccines for SUDs. Although early preclinical animal studies were optimistic and successful, few vaccines have reached human clinical trials. Only nicotine and cocaine vaccines have successfully advanced to Phase 3 clinical trials and neither are currently available as a treatment option. Various innovative approaches in vaccine design have been made to overcome limitations and improve immunogenicity, including the use of nanoparticles, synthetic haptens, and more immunogenic adjuvants. While success has thus far been elusive, with substantial scientific advancements in vaccine technology, immunotherapy remains a promising and viable option for the treatment of SUDs.

Citing Articles

The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention.

Tuncturk M, Kushwaha S, Heider BS R, Heider R, Oesterle T, Weinshilboum R Int J Neuropsychopharmacol. 2025; 28(2).

PMID: 39831679 PMC: 11792077. DOI: 10.1093/ijnp/pyaf005.

Application of microbial enzymes in medicine and industry: current status and future perspectives.

Darbandi A, Elahi Z, Dadgar-Zankbar L, Ghasemi F, Kakavandi N, Jafari S Future Microbiol. 2024; 19(16):1419-1437.

PMID: 39269849 PMC: 11552484. DOI: 10.1080/17460913.2024.2398337.

COT-TT vaccine attenuates cocaine-seeking and cocaine-conditioned place preference in rats.

Barbosa-Mendez S, Matus-Ortega M, Hernandez-Miramontes R, Salazar-Juarez A Hum Vaccin Immunother. 2024; 20(1):2299068.

PMID: 38228468 PMC: 10793666. DOI: 10.1080/21645515.2023.2299068.

New medications development for smoking cessation.

Lengel D, Kenny P Addict Neurosci. 2023; 7.

PMID: 37519910 PMC: 10373598. DOI: 10.1016/j.addicn.2023.100103.

Chemical tools for the opioids.

Duque M, Vallavoju N, Woo C Mol Cell Neurosci. 2023; 125:103845.

PMID: 36948231 PMC: 10247539. DOI: 10.1016/j.mcn.2023.103845.

References

Nguyen H, Park J, Kang S, Kim M . Surface plasmon resonance: a versatile technique for biosensor applications. Sensors (Basel). 2015; 15(5):10481-510. PMC: 4481982. DOI: 10.3390/s150510481. View

Bell J, Strang J . Medication Treatment of Opioid Use Disorder. Biol Psychiatry. 2019; 87(1):82-88. DOI: 10.1016/j.biopsych.2019.06.020. View

Rosenberg J, Hicks M, De B, Pagovich O, Frenk E, Janda K . AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum Gene Ther. 2012; 23(5):451-9. PMC: 3360503. DOI: 10.1089/hum.2011.178. View

Brimijoin S, Gao Y, Anker J, Gliddon L, Lafleur D, Shah R . A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology. 2008; 33(11):2715-25. PMC: 2562914. DOI: 10.1038/sj.npp.1301666. View

Howell L, Nye J, Stehouwer J, Voll R, Mun J, Narasimhan D . A thermostable bacterial cocaine esterase rapidly eliminates cocaine from brain in nonhuman primates. Transl Psychiatry. 2014; 4:e407. PMC: 4119218. DOI: 10.1038/tp.2014.48. View

Torres O, Antoline J, Li F, Jalah R, Jacobson A, Rice K . A simple nonradioactive method for the determination of the binding affinities of antibodies induced by hapten bioconjugates for drugs of abuse. Anal Bioanal Chem. 2015; 408(4):1191-204. PMC: 4718952. DOI: 10.1007/s00216-015-9223-z. View

Cornish K, Harris A, Lesage M, Keyler D, Burroughs D, Earley C . Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy. Int Immunopharmacol. 2011; 11(11):1809-15. PMC: 3204179. DOI: 10.1016/j.intimp.2011.07.009. View

Kosten T, Shen X, OMalley P, Kinsey B, Lykissa E, Orson F . A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45:223-9. PMC: 3773503. DOI: 10.1016/j.pnpbp.2013.05.012. View

Peterson E, Gunnell M, Che Y, Goforth R, Carroll F, Henry R . Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther. 2007; 322(1):30-9. DOI: 10.1124/jpet.106.117150. View

10.

Mounteney J, Giraudon I, Denissov G, Griffiths P . Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Policy. 2015; 26(7):626-31. DOI: 10.1016/j.drugpo.2015.04.003. View

11.

Karila L, Weinstein A, Aubin H, Benyamina A, Reynaud M, Batki S . Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010; 69(6):578-92. PMC: 2883750. DOI: 10.1111/j.1365-2125.2010.03639.x. View

12.

Raleigh M, Pravetoni M, Harris A, Birnbaum A, Pentel P . Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther. 2012; 344(2):397-406. PMC: 3558830. DOI: 10.1124/jpet.112.201194. View

13.

Kosten T, Domingo C, Hamon S, Nielsen D . DBH gene as predictor of response in a cocaine vaccine clinical trial. Neurosci Lett. 2013; 541:29-33. PMC: 3631430. DOI: 10.1016/j.neulet.2013.02.037. View

14.

Moreno A, Mayorov A, Janda K . Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc. 2011; 133(17):6587-95. PMC: 3090292. DOI: 10.1021/ja108807j. View

15.

Narasimhan D, Woods J, Sunahara R . Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction. Future Med Chem. 2012; 4(2):137-50. PMC: 3290992. DOI: 10.4155/fmc.11.194. View

16.

Bremer P, Janda K . Conjugate Vaccine Immunotherapy for Substance Use Disorder. Pharmacol Rev. 2017; 69(3):298-315. PMC: 5482184. DOI: 10.1124/pr.117.013904. View

17.

Cahill K, Stevens S, Perera R, Lancaster T . Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; (5):CD009329. PMC: 8406789. DOI: 10.1002/14651858.CD009329.pub2. View

18.

Winger G, Hursh S, Casey K, Woods J . Relative reinforcing strength of three N-methyl-D-aspartate antagonists with different onsets of action. J Pharmacol Exp Ther. 2002; 301(2):690-7. DOI: 10.1124/jpet.301.2.690. View

19.

Heekin R, Shorter D, Kosten T . Current status and future prospects for the development of substance abuse vaccines. Expert Rev Vaccines. 2017; 16(11):1067-1077. DOI: 10.1080/14760584.2017.1378577. View

20.

Selley D, Cao C, Sexton T, Schwegel J, Martin T, Childers S . mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem Pharmacol. 2001; 62(4):447-55. DOI: 10.1016/s0006-2952(01)00689-x. View